JP2015504430A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504430A5
JP2015504430A5 JP2014542299A JP2014542299A JP2015504430A5 JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5 JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5
Authority
JP
Japan
Prior art keywords
antagonist
allele
seq
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041310 external-priority patent/WO2013077907A1/en
Publication of JP2015504430A publication Critical patent/JP2015504430A/ja
Publication of JP2015504430A5 publication Critical patent/JP2015504430A5/ja
Pending legal-status Critical Current

Links

JP2014542299A 2011-11-21 2012-06-07 Il−7アンタゴニスト及びpsa応答又は非応答対立遺伝子を用いた乾癬性関節炎(psa)を治療する方法 Pending JP2015504430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IQ370/2011 2011-11-21
IQ3702011 2011-11-21
US201261624564P 2012-04-16 2012-04-16
US61/624,564 2012-04-16
PCT/US2012/041310 WO2013077907A1 (en) 2011-11-21 2012-06-07 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles

Publications (2)

Publication Number Publication Date
JP2015504430A JP2015504430A (ja) 2015-02-12
JP2015504430A5 true JP2015504430A5 (enExample) 2015-07-23

Family

ID=48470189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542299A Pending JP2015504430A (ja) 2011-11-21 2012-06-07 Il−7アンタゴニスト及びpsa応答又は非応答対立遺伝子を用いた乾癬性関節炎(psa)を治療する方法

Country Status (12)

Country Link
US (1) US20150064193A1 (enExample)
EP (1) EP2783014A1 (enExample)
JP (1) JP2015504430A (enExample)
KR (1) KR20140097178A (enExample)
CN (1) CN104011223A (enExample)
AR (1) AR086907A1 (enExample)
AU (1) AU2012341081B2 (enExample)
BR (1) BR112014012101A2 (enExample)
CA (1) CA2856252A1 (enExample)
MX (1) MX2014006158A (enExample)
RU (1) RU2014125071A (enExample)
WO (1) WO2013077907A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドModernaTX,Inc. 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN113368233A (zh) 2014-05-15 2021-09-10 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US20160244520A1 (en) * 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
SG11201802887PA (en) 2015-10-27 2018-05-30 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
MA55149A (fr) * 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CA3142667A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20220066318A (ko) * 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
EP4305062A1 (en) * 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
AU2022233792A1 (en) * 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN114427001A (zh) * 2022-01-29 2022-05-03 中日友好医院(中日友好临床医学研究所) 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2690568A1 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
WO2011014349A1 (en) * 2009-07-28 2011-02-03 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis
NO2625199T3 (enExample) * 2010-10-08 2018-04-21
AR084234A1 (es) * 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)

Similar Documents

Publication Publication Date Title
JP2015504430A5 (enExample)
RU2014125071A (ru) Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
US12269873B2 (en) Signature of TL1A (TNFSF15) signaling pathway
JP2017513937A5 (enExample)
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
US20100316608A1 (en) Method of Determining A Response To Treatment With Immunomodulatory Composition
CA2714410A1 (en) Disease markers and uses thereof
JP2009039107A5 (enExample)
van Sorge et al. Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms
JP2017519498A5 (enExample)
WO2016022589A2 (en) Methods for treating multiple myeloma
CN102808030B (zh) 单核苷多态性rs3888188在检测结核病易感性中的应用
CN109837345B (zh) 检测小鼠细胞残留dna的引物及方法
US20210148910A1 (en) Compositions and methods for treatment of atopic dermatitis and treatment selection
US20100092468A1 (en) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
Phuangtham et al. Human platelet antigens in Burmese, Karen and north‐eastern Thais
JP2019520355A5 (enExample)
WO2013107005A1 (zh) 人稀有血型的多重pcr检测方法和试剂盒
KR20220061425A (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US20180258475A1 (en) Method and device for snp genotyping
Parasannanavar et al. HLA-DRβ1* 04 typing by simple in-house PCR-SSP technique for rheumatoid arthritis patients
JP2009225713A (ja) インフリキシマブの有効性判定方法
CN115976183A (zh) 预测干扰素α对乙型肝炎患者治疗疗效的分子标记及其应用